TREVICTA 263 mg, suspension for injection with extended release syringe, 1.315 ml
Active ingredients: PALIPÉRIDONE, Paliperidone palmitate
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for injection with extended releasesyringe, 1.315 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TREVICTA 263 mg, suspension injectable à libération prolongée
- Pharmaceutical form
- suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 seringue préremplie en copolymère de cyclooléfines de 1,315 ml (200 mg/ml) avec 2 aiguille(s)
- Marketing authorisation holder
- JANSSEN CILAG INTERNATIONAL NV
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 6 Feb 2017
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a specialist
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69642982CIP73005982CIP133400930059821Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PALIPÉRIDONEsuspension | 263 mg · une seringue préremplie | FT |
| PALMITATE DE PALIPÉRIDONEsuspension | 410 mg · une seringue préremplie | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.